Entinostat (MS-275)

For research use only.

Catalog No.S1053 Synonyms: SNDX-275

288 publications

Entinostat (MS-275) Chemical Structure

CAS No. 209783-80-2

Entinostat (MS-275, SNDX-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat induces autophagy and apoptosis. Phase 3.

Size Price Stock Quantity  
10mM (1mL in DMSO) RMB 746.45 In stock
RMB 466.83 In stock
RMB 564.33 In stock
RMB 1233.32 In stock
RMB 2234.07 In stock
RMB 6301.79 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Entinostat (MS-275) has been cited by 288 publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Entinostat (MS-275, SNDX-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat induces autophagy and apoptosis. Phase 3.
Targets
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 M1zVcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLoTWM2OD1yLkC2NUDPxE1? NYHtdWs2W0GQR1XS
ALL-PO NUG1elNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwME[zOVUh|ryP NY\6RWhzW0GQR1XS
697 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkO1TWM2OD1yLkC5PVc3KM7:TR?= NW[wd3BtW0GQR1XS
NCI-H748 MojPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTBwMUCzN|Qh|ryP M4KwenNCVkeHUh?=
NKM-1 M3frWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwMUC5NVIh|ryP NW[wO5REW0GQR1XS
ES1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnWOGU4UUN3ME2wMlEyOjV3IN88US=> M1TxRnNCVkeHUh?=
NCI-H1963 NEjKN5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPlTWM2OD1yLkGxOVc6KM7:TR?= MVvTRW5ITVJ?
NCI-H1417 MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPWTWM2OD1yLkGyPVc1KM7:TR?= M2jUTHNCVkeHUh?=
NEC8 MofOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TJcGlEPTB;MD6xN|UzPyEQvF2= NYHKRlE3W0GQR1XS
CRO-AP2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTBwMU[4PFkh|ryP M4ntSXNCVkeHUh?=
A3-KAW Mn\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nTPGlEPTB;MD6xO|YzPyEQvF2= MVnTRW5ITVJ?
SF539 Mn:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLOZWtKSzVyPUCuNVk2QTNizszN MYrTRW5ITVJ?
NOS-1 Mmq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofxTWM2OD1yLkG5OlE6KM7:TR?= NWHkWIdbW0GQR1XS
NTERA-S-cl-D1 M2njSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXDTHpHUUN3ME2wMlIxOTF|IN88US=> MoPUV2FPT0WU
COR-L88 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTBwMkK5OVkh|ryP NUXpfFhWW0GQR1XS
EM-2 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFOxVoRKSzVyPUCuNlQxPzlizszN M{ixPHNCVkeHUh?=
KARPAS-45 NGTWfItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\2TWM2OD1yLkK3PFM{KM7:TR?= M4LpeXNCVkeHUh?=
DSH1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonLTWM2OD1yLkK4O|A5KM7:TR?= MV3TRW5ITVJ?
HT-144 NGfLOINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLkfIlYUUN3ME2wMlMxOjV4IN88US=> NIDtcnpUSU6JRWK=
ATN-1 MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwM{C1O|Yh|ryP NX70RmZyW0GQR1XS
HEL NVjaWHJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvHTWM2OD1yLkOxN|Q5KM7:TR?= NYe2N3hSW0GQR1XS
NB12 NGHSUXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfwOVlMUUN3ME2wMlMyPzV4IN88US=> NYPR[|dIW0GQR1XS
LU-139 M16weWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2SwTmlEPTB;MD6zN|UyKM7:TR?= NH;xT5hUSU6JRWK=
J-RT3-T3-5 M3zRfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETJdJRKSzVyPUCuN|M4OTZizszN MlfrV2FPT0WU
MOLT-13 NH:3[G5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTBwM{O4NUDPxE1? NFnWPZNUSU6JRWK=
SR NVPnepkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwM{SyOlEh|ryP NUHieGl6W0GQR1XS
CMK M{DXVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3f5dmlEPTB;MD6zOVczPyEQvF2= M3:0RnNCVkeHUh?=
ES8 MonMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nnSGlEPTB;MD6zOlAzOiEQvF2= M{HMbHNCVkeHUh?=
LB647-SCLC M33nO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XuemlEPTB;MD6zOlc{KM7:TR?= MV7TRW5ITVJ?
TE-8 NVGwSo5lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUn2c|FDUUN3ME2wMlM3QTN3IN88US=> MoK0V2FPT0WU
BV-173 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHPTWM2OD1yLkO3NVIyKM7:TR?= NVLZWnBKW0GQR1XS
DEL M4j5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrDUZBKSzVyPUCuN|c1QDdizszN NFPtVFZUSU6JRWK=
ARH-77 M2naVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTBSGdyUUN3ME2wMlM5OTl|IN88US=> MXrTRW5ITVJ?
NCCIT NHrRd4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrETWM2OD1yLkO4OlQ6KM7:TR?= NFrIUGZUSU6JRWK=
RPMI-8402 NFL3RZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwM{i3NFEh|ryP MVnTRW5ITVJ?
MONO-MAC-6 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPVe2JKSzVyPUCuN|g4PzZizszN Mn3CV2FPT0WU
SK-MM-2 NEH0[21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3yTWM2OD1yLkO5PFY5KM7:TR?= NGLDT3BUSU6JRWK=
CHP-126 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkC2TWM2OD1yLkSwNlMyKM7:TR?= M4iwTXNCVkeHUh?=
A101D NHXyXmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHFTWM2OD1yLkSwN{DPxE1? M{Xj[HNCVkeHUh?=
SCH NIjNfG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW[4epNXUUN3ME2wMlQxOzR{IN88US=> NFnzN4JUSU6JRWK=
NMC-G1 MkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHmNWJCUUN3ME2wMlQxOzZ5IN88US=> MojrV2FPT0WU
NCI-H209 Mn;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDZ[WpZUUN3ME2wMlQxPjF|IN88US=> MWTTRW5ITVJ?
MOLT-16 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwNEGwNVch|ryP NWqzVJpYW0GQR1XS
RPMI-6666 M3jNTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnqzTWM2OD1yLkSxNVIh|ryP NXLSPJFNW0GQR1XS
OPM-2 M1PjNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTBwNEG1NVMh|ryP NHvPW25USU6JRWK=
MRK-nu-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3T4ZmlEPTB;MD60N|E2OyEQvF2= NUP0OXRyW0GQR1XS
BC-1 M1n4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPwN21oUUN3ME2wMlQ{PDB|IN88US=> M{mzbHNCVkeHUh?=
MHH-NB-11 NH7DblhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfFXnVKSzVyPUCuOFM1PTNizszN NUTSWFB3W0GQR1XS
Ramos-2G6-4C10 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWD1PI95UUN3ME2wMlQ{QDl5IN88US=> NInmdGVUSU6JRWK=
LS-513 NX;5RZJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorRTWM2OD1yLkS0OVAyKM7:TR?= M{jkT3NCVkeHUh?=
K5 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\T[WxKSzVyPUCuOFcxOjVizszN NUOxNW14W0GQR1XS
HOP-62 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTWZXlJUUN3ME2wMlQ5OzV6IN88US=> M1TX[nNCVkeHUh?=
NCI-H187 M1HDXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDYTWM2OD1yLkS5NlI4KM7:TR?= MlrvV2FPT0WU
BE-13 M{jrVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\JSW5wUUN3ME2wMlQ6PjZzIN88US=> NFKzZ5ZUSU6JRWK=
HC-1 M2fv[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELOVVlKSzVyPUCuOVA1PzNizszN M1q1OnNCVkeHUh?=
ACN NYHwNY5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M362[mlEPTB;MD61NVAzQCEQvF2= M4PudHNCVkeHUh?=
HCC1599 NIDxSlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jtbGlEPTB;MD61NVU4KM7:TR?= NIDySIRUSU6JRWK=
MV-4-11 MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\EXmlEPTB;MD61N|A1OSEQvF2= MXLTRW5ITVJ?
LC-2-ad M4Dq[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUn6[GZCUUN3ME2wMlU{PjZ|IN88US=> MVrTRW5ITVJ?
HL-60 M3rIPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnj4TWM2OD1yLkW0NlYyKM7:TR?= NIfDPFNUSU6JRWK=
NB17 NETCbIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnFSFNKSzVyPUCuOVQ{QCEQvF2= NYr4[JZ2W0GQR1XS
TE-1 NXjvTVNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVO0cJZ1UUN3ME2wMlU2OzB4IN88US=> NILTSXRUSU6JRWK=
NCI-H524 NYXHUIxyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnqzTWM2OD1yLkW1OFAyKM7:TR?= NIfVcpBUSU6JRWK=
MZ7-mel NHLqRoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwNU[xNFUh|ryP MXrTRW5ITVJ?
L-363 NWTIb4hmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwNU[2OVch|ryP NEfKXG9USU6JRWK=
BL-41 NIrwOWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jmZ2lEPTB;MD61Olg5QSEQvF2= MnTiV2FPT0WU
LU-134-A MmX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfxTWM2OD1yLkW3NFc{KM7:TR?= NV7qV5J4W0GQR1XS
SIG-M5 NX;FeGROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTBwNUe4OFgh|ryP Mk\SV2FPT0WU
ONS-76 MoHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXftc25WUUN3ME2wMlU5OjR{IN88US=> MkDhV2FPT0WU
KARPAS-299 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTCTWM2OD1yLkW4OVA1KM7:TR?= MV\TRW5ITVJ?
DU-4475 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYX4ZWZIUUN3ME2wMlU5PzB|IN88US=> M4TYRXNCVkeHUh?=
NB69 M{Hicmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTBwNUm4NlUh|ryP MXfTRW5ITVJ?
MHH-PREB-1 M4XWU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGL6NIRKSzVyPUCuOlA4OTlizszN NGHOUFRUSU6JRWK=
LU-165 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGGzelNKSzVyPUCuOlE5OTJizszN MWTTRW5ITVJ?
LOUCY MoTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTBwNkOzOlQh|ryP MXPTRW5ITVJ?
NCI-H526 M{[0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml[2TWM2OD1yLk[zOVQyKM7:TR?= NEnTTpZUSU6JRWK=
KE-37 NV30W4FGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3X4ZWlEPTB;MD62OFI4PiEQvF2= NVWyeno1W0GQR1XS
NALM-6 Ml:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwNkS4OkDPxE1? MX;TRW5ITVJ?
CW-2 NFrjN|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwNkW3PVQh|ryP MULTRW5ITVJ?
SU-DHL-1 Ml7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXPU2ZwUUN3ME2wMlY2QTR5IN88US=> M4nsXnNCVkeHUh?=
NB13 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnnUJRsUUN3ME2wMlY3QDF5IN88US=> MoHFV2FPT0WU
QIMR-WIL M3\YdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnQPWtwUUN3ME2wMlY5OzR|IN88US=> M{ezV3NCVkeHUh?=
ECC12 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILFcZpKSzVyPUCuO|AxQDZizszN NEmzVphUSU6JRWK=
KALS-1 Mm\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPTPJVKSzVyPUCuO|A1QTJizszN NGrVTZRUSU6JRWK=
COR-L279 M2fCO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvHWIp6UUN3ME2wMlcxQTl4IN88US=> NUnlbGxNW0GQR1XS
NB14 M1zFXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTBwN{K2NVch|ryP MYnTRW5ITVJ?
CCRF-CEM MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTBwN{S2OlEh|ryP M1[5WnNCVkeHUh?=
SW954 NEXufXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nOS2lEPTB;MD63OVk6QSEQvF2= MkCxV2FPT0WU
IST-SL1 NVjuOHBjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LnVmlEPTB;MD63O|M1QCEQvF2= M3vmOnNCVkeHUh?=
LAMA-84 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHubmsxUUN3ME2wMlc4PTZ5IN88US=> MXnTRW5ITVJ?
Daudi NYD6ZW5{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvLTWM2OD1yLke3OlgyKM7:TR?= MlK1V2FPT0WU
BC-3 NGPhdoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTBwN{izNFgh|ryP M{\DRXNCVkeHUh?=
HCC2998 M2n4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwN{izOkDPxE1? MWfTRW5ITVJ?
NCI-H69 MlXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXvTZpJUUN3ME2wMlgxOTR5IN88US=> MmrRV2FPT0WU
CPC-N MmH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7ienZRUUN3ME2wMlgxPTJ2IN88US=> MWHTRW5ITVJ?
NOMO-1 MlvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;5TWM2OD1yLkixNFg1KM7:TR?= NILiZ2JUSU6JRWK=
CESS NFzpU2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTBwOEGxPVch|ryP NWjibGNPW0GQR1XS
LC4-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nsSWlEPTB;MD64OFAxPyEQvF2= MmX3V2FPT0WU
BL-70 NGTZUGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3jTWM2OD1yLki1O|AzKM7:TR?= MVjTRW5ITVJ?
ES4 M4T0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwOEW4Olgh|ryP M1;HdHNCVkeHUh?=
HCE-T M4LwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGG5OFlKSzVyPUCuPFcyPzFizszN MXLTRW5ITVJ?
JAR M3jwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXSybYlVUUN3ME2wMlg4QDJ5IN88US=> NUXNU45pW0GQR1XS
ST486 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXGcolQUUN3ME2wMlg4QTF5IN88US=> M2jFbXNCVkeHUh?=
KS-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwOEiwPVYh|ryP NUPEbmlOW0GQR1XS
GDM-1 NX7jSmpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jjWmlEPTB;MD64PFY5PyEQvF2= M3naWXNCVkeHUh?=
EHEB NXHrdGlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTBwOUK1PFUh|ryP MYPTRW5ITVJ?
LB2518-MEL MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1[5TGlEPTB;MD65N|I5PCEQvF2= MlTyV2FPT0WU
GOTO MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13YbGlEPTB;MD65OVA4PiEQvF2= MorxV2FPT0WU
LXF-289 NHL2fohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TsZWlEPTB;MD65OVkxOSEQvF2= M1\meXNCVkeHUh?=
ES6 M1f5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1SyfmlEPTB;MD65OlQ{PyEQvF2= MYfTRW5ITVJ?
OS-RC-2 MmLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkL3TWM2OD1yLkm2PFMh|ryP MVjTRW5ITVJ?
DMS-153 NHXIOW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\EXlJKSzVyPUCuPVc1PjlizszN MkjPV2FPT0WU
SK-PN-DW NWPXSGFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPGUHFKSzVyPUCuPVc5OzFizszN MmXDV2FPT0WU
HH NH:w[|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXUTWM2OD1yLkm4PVU6KM7:TR?= MnT3V2FPT0WU
SH-4 NEPFWVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHq2eIJKSzVyPUGuNFI1OSEQvF2= M3u1dnNCVkeHUh?=
MOLT-4 Ml;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;KWppVUUN3ME2xMlA{PDV2IN88US=> NUPyTWJDW0GQR1XS
TGW NI\rdGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVviNplRUUN3ME2xMlA4Pjd3IN88US=> MWfTRW5ITVJ?
L-540 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmC5TWM2OD1zLkGwOlA1KM7:TR?= NGXBPGZUSU6JRWK=
PF-382 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTFwMUG1NVMh|ryP M1n6cnNCVkeHUh?=
LC-1F Mle4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmH1TWM2OD1zLkGyNFA4KM7:TR?= NUPFXVF[W0GQR1XS
OVCAR-4 NHXZTlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1:wbGlEPTB;MT6xN|E3PSEQvF2= NIPyNoVUSU6JRWK=
A4-Fuk NX7FbHRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3m1S2lEPTB;MT6xOVM3PCEQvF2= NF;6emFUSU6JRWK=
HCC2218 NYLTVG52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2SwdGlEPTB;MT6xOlY1OSEQvF2= Mn7HV2FPT0WU
HAL-01 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3:1bGlEPTB;MT6xOlk1OyEQvF2= NY\sNnpPW0GQR1XS
IST-MEL1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTFwMUe2OVkh|ryP NFHNeXFUSU6JRWK=
NCI-H719 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTFwMUe4PVgh|ryP MU\TRW5ITVJ?
EVSA-T M3zyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTFwMUixNVQh|ryP M3XTUnNCVkeHUh?=
SK-NEP-1 M2XoUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzzTWM2OD1zLkKwNlY3KM7:TR?= NWjLdYdZW0GQR1XS
OCUB-M NITKS|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFuwSY9KSzVyPUGuNlE1QDlizszN M1;LSHNCVkeHUh?=
MEG-01 NFHlS5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTFwMkKxNVgh|ryP M37iR3NCVkeHUh?=
no-10 MoLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTFwMkOxNVIh|ryP NVv6UpRCW0GQR1XS
MHH-CALL-2 M4qzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:wcoN2UUN3ME2xMlI1PzJzIN88US=> MkfQV2FPT0WU
SK-N-DZ M1nqN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTFwMkS3O|Yh|ryP NH7E[GRUSU6JRWK=
SCLC-21H NIDXRYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\WTWM2OD1zLkK2OFc5KM7:TR?= MoG1V2FPT0WU
CTV-1 NYWwclR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjyPVFKSzVyPUGuNlc1OjVizszN M{jDN3NCVkeHUh?=
NB1 MnPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PCb2lEPTB;MT6yO|c{OiEQvF2= NV7SfZZKW0GQR1XS
NCI-H64 MmPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLVTWM2OD1zLkK4OFYzKM7:TR?= NUSwXmdiW0GQR1XS
MDA-MB-134-VI M4HMOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTFwMki1O|ch|ryP M2rGWHNCVkeHUh?=
LB2241-RCC MlPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn24TWM2OD1zLkK4OlY{KM7:TR?= MoDyV2FPT0WU
8-MG-BA NILMSmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIi5U4JKSzVyPUGuNlg5PjZizszN MVfTRW5ITVJ?
LP-1 NH7FUJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;Cc2lEPTB;MT6yPVk1PyEQvF2= M1LYeXNCVkeHUh?=
LS-411N NWHhbo5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7RNmVKSzVyPUGuN|A6QThizszN MVXTRW5ITVJ?
CAL-148 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnPSGpKSzVyPUGuN|I2PDJizszN M125OXNCVkeHUh?=
NCI-H2171 MnHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPmN4c4UUN3ME2xMlM1PTB{IN88US=> MmO4V2FPT0WU
JiyoyeP-2003 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HScGlEPTB;MT6zOVM6KM7:TR?= M{GxPHNCVkeHUh?=
NCI-H2107 Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTFwM{W4PFMh|ryP NED4[5JUSU6JRWK=
BB30-HNC NFnENHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2S5fGlEPTB;MT6zPFk4QCEQvF2= MVnTRW5ITVJ?
K-562 MnO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\mTWVKSzVyPUGuN|kzOTlizszN NFn5OY9USU6JRWK=
PSN1 NUDyPJVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTFwNEKyPFch|ryP M1H6[XNCVkeHUh?=
HCC2157 M3XqOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\HTWM2OD1zLkSyOlkyKM7:TR?= NGnXe|JUSU6JRWK=
SBC-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37MbmlEPTB;MT60Nlc1OSEQvF2= NF:5ZXBUSU6JRWK=
MC116 NIrYcplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHLTmtKSzVyPUGuOFM3OTVizszN NWLMNoFxW0GQR1XS
KARPAS-422 NWTRRXRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTFwNEWzOVgh|ryP MVHTRW5ITVJ?
LB996-RCC M3Pyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTJO44zUUN3ME2xMlQ4OTB|IN88US=> MlvrV2FPT0WU
MSTO-211H NEHpT4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrtTFVFUUN3ME2xMlQ4QTh5IN88US=> MW\TRW5ITVJ?
BT-474 M1nyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjTVHcyUUN3ME2xMlUyPzZ2IN88US=> MmfJV2FPT0WU
A388 MkXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;5fGRKSzVyPUGuOVE6PDVizszN NH:2VZJUSU6JRWK=
SJSA-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGL1OXdKSzVyPUGuOVIzPiEQvF2= M3vqWHNCVkeHUh?=
COLO-829 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml:2TWM2OD1zLkWzOVY1KM7:TR?= M{DRZXNCVkeHUh?=
KM-H2 MlnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DJ[GlEPTB;MT61OlY4KM7:TR?= MXvTRW5ITVJ?
GR-ST NV3m[Vk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nMW2lEPTB;MT61OlgzKM7:TR?= NYezclR4W0GQR1XS
RPMI-8866 NV3pOo1RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M12xOGlEPTB;MT62NFE1PCEQvF2= MlPBV2FPT0WU
KG-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIO0TlZKSzVyPUGuOlE6ODFizszN NEDCOllUSU6JRWK=
NCI-H82 M4\Hdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLaTWM2OD1zLk[zOFA3KM7:TR?= Mny3V2FPT0WU
LB1047-RCC MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLtfFlKSzVyPUGuOlM1PTlizszN Mn3OV2FPT0WU
KM12 M2X3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFi5R2dKSzVyPUGuOlQ4KM7:TR?= NW\PUGpKW0GQR1XS
NB5 NYjuO4dkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\BeVhCUUN3ME2xMlY2Pjd5IN88US=> M3XETHNCVkeHUh?=
HDLM-2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TQV2lEPTB;MT62PFI5OSEQvF2= M3:2[3NCVkeHUh?=
KU812 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEKzVHFKSzVyPUGuOlk3ODVizszN MnnuV2FPT0WU
DB MnjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVj5Z|dSUUN3ME2xMlcxOzV|IN88US=> NWG3ZlhnW0GQR1XS
HD-MY-Z MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTFwN{WyN|Qh|ryP MYLTRW5ITVJ?
KURAMOCHI MlTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLhTWM2OD1zLke3NlA4KM7:TR?= NVHvXnpCW0GQR1XS
ETK-1 NYOwNohST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTFwN{i4O|kh|ryP NWjKdItYW0GQR1XS
SK-UT-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3K[olQUUN3ME2xMlc6Ozh6IN88US=> MXjTRW5ITVJ?
HUTU-80 MkXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1L3eGlEPTB;MT63PVUxQCEQvF2= M{DpTXNCVkeHUh?=
ES7 M{HOUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTFwOECzNFIh|ryP NU\pPWJJW0GQR1XS
SW872 M2fqUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTFwOEGzPVUh|ryP MnjDV2FPT0WU
TK10 NHX5XZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTFwOEOxNFgh|ryP MYjTRW5ITVJ?
LB831-BLC NVXFTGhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFm2eYJKSzVyPUGuPFM2PjNizszN NE\JXGdUSU6JRWK=
TE-9 MlXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfHZ|JFUUN3ME2xMlg1PDJ{IN88US=> M1vvVnNCVkeHUh?=
MLMA MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTFwOEiyN|Qh|ryP M2XoZ3NCVkeHUh?=
D-542MG NF\kOHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PPdWlEPTB;MT64PVM4OyEQvF2= NI\2OmRUSU6JRWK=
EW-16 NX7ub2RJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPl[5I4UUN3ME2xMlkzPzJizszN MWDTRW5ITVJ?
LOXIMVI MlvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIH4fpZKSzVyPUGuPVMzQCEQvF2= MXrTRW5ITVJ?
GB-1 MmrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTFwOUO4OlYh|ryP MkLHV2FPT0WU
IST-SL2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TOXGlEPTB;Mj6wNFI3OiEQvF2= MVfTRW5ITVJ?
LAN-6 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXW0XIY3UUN3ME2yMlAyQTZ4IN88US=> Mkj5V2FPT0WU
NCI-H510A NYrmV5pwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\pbI9LUUN3ME2yMlA1PTB{IN88US=> MlXGV2FPT0WU
NCI-H1092 M2HY[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTQTWM2OD1{LkC1NVI1KM7:TR?= MX\TRW5ITVJ?
HT MnvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3abYxKSzVyPUKuNVA1PTRizszN MV;TRW5ITVJ?
RL95-2 MlvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLlbGVHUUN3ME2yMlEyPDh{IN88US=> NULMWFhNW0GQR1XS
NCI-H1355 NYPMdY5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3DTWM2OD1{LkGxO|kzKM7:TR?= MX;TRW5ITVJ?
NCI-H720 Ml3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTJwMU[4O|Mh|ryP MorIV2FPT0WU
NCI-H1522 NW\VdVR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHz4NY5KSzVyPUKuNlE4OjNizszN M4ThN3NCVkeHUh?=
LB373-MEL-D NYO4RpY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojDTWM2OD1{LkK2PVAzKM7:TR?= MUDTRW5ITVJ?
DG-75 MoHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;3W2lEPTB;Mj6yO|E1QCEQvF2= NV;KbYNxW0GQR1XS
ML-2 M3;UXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\sWGZKSzVyPUKuN|I5PTVizszN M1faSXNCVkeHUh?=
SF126 M{PDdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrqTWM2OD1{LkOzNFk1KM7:TR?= MY\TRW5ITVJ?
MPP-89 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{OwRWlEPTB;Mj6zN|E1PSEQvF2= NYX2OXZyW0GQR1XS
NCI-H345 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTJwM{OyO|ch|ryP NXvzWFQ4W0GQR1XS
LS-123 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjXU2U5UUN3ME2yMlM1QTN4IN88US=> MUTTRW5ITVJ?
NB10 MnrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjKWYY6UUN3ME2yMlQyODl{IN88US=> NInRemZUSU6JRWK=
CGTH-W-1 NHyxdJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rXRmlEPTB;Mj60NlI3PyEQvF2= NXj3TZNMW0GQR1XS
CP66-MEL NXXLUmhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnn5TWM2OD1{LkS3O|ch|ryP NXLYU3dpW0GQR1XS
L-428 NFPTTHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTJwNEi1NlEh|ryP MVLTRW5ITVJ?
DMS-79 NYPVRYZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTJwNUSxNFMh|ryP NYriZoRxW0GQR1XS
NCI-H1882 M{PEdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFj3d|BKSzVyPUKuOlc2PjJizszN NFq2TotUSU6JRWK=
KGN MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\4TWM2OD1{Lke2PFc3KM7:TR?= M3joSnNCVkeHUh?=
EW-1 NXu4fIdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLKNmJ[UUN3ME2yMlc4ODh|IN88US=> MnLPV2FPT0WU
U-266 NIHNWZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rhWWlEPTB;Mj64OFgzOyEQvF2= NHGwc|FUSU6JRWK=
COLO-320-HSR MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkL6TWM2OD1{Lki1OlQyKM7:TR?= Ml;DV2FPT0WU
KMOE-2 MlfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTJwOEe3NVEh|ryP NUC0OlUxW0GQR1XS
BB49-HNC NY\HR5lRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTJwOUK0PEDPxE1? NX3UPWU6W0GQR1XS
GI-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTJwOUK5OVch|ryP MU\TRW5ITVJ?
NCI-H1304 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TuSmlEPTB;Mz6wNFUyOSEQvF2= NGfwcFdUSU6JRWK=
NCI-H2227 M{H2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1j1UmlEPTB;Mz6wNlA4QSEQvF2= M4Twe3NCVkeHUh?=
U-87-MG M3W4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jIdGlEPTB;Mz6wN|UyOyEQvF2= M3j5WHNCVkeHUh?=
NCI-H747 M{\W[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXaTWM2OD1|LkC1NlA3KM7:TR?= M4TDXXNCVkeHUh?=
CTB-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnxVIk1UUN3ME2zMlA2Ozd4IN88US=> NYXESXpmW0GQR1XS
RPMI-8226 NFfvTGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTNwMUSzO|gh|ryP M1HQTHNCVkeHUh?=
NCI-H2141 NEDEUZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTNdWY5UUN3ME2zMlE3PTZ4IN88US=> M3\kdXNCVkeHUh?=
IST-MES1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTNwMUiyO|kh|ryP NWXHNmw4W0GQR1XS
TE-5 NUDHeZdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmK4TWM2OD1|LkKxN|QzKM7:TR?= M1rSSnNCVkeHUh?=
UACC-257 Mlu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTNwNEO2OVkh|ryP MlnDV2FPT0WU
SK-N-FI NXnZTnFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTNwNEWyNlch|ryP Mn3vV2FPT0WU
MFH-ino NEnjcZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPtTWM2OD1|LkS2OVg6KM7:TR?= NGTDeVhUSU6JRWK=
SF268 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoG5TWM2OD1|LkS4NVc1KM7:TR?= NWSxUotKW0GQR1XS
TE-12 NGDoRZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTNwNUG2PVkh|ryP M2fVZnNCVkeHUh?=
NB6 NF72TJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTNwNUW1OlMh|ryP MnH3V2FPT0WU
DJM-1 M1HHU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;ub2lEPTB;Mz61PVg6QSEQvF2= MmrLV2FPT0WU
MZ1-PC MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1f0e2lEPTB;Mz62NVYzPCEQvF2= NWG2fmlHW0GQR1XS
OCI-AML2 M3Tlcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfWVXNKSzVyPUOuOlI3PzFizszN NYfiWFc4W0GQR1XS
NCI-H1155 MlfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTNwN{C5OFch|ryP M4S2eHNCVkeHUh?=
RKO MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUSzN2RiUUN3ME2zMlc4OTh7IN88US=> NEPnW5VUSU6JRWK=
ECC4 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLJTI91UUN3ME2zMlk4OTl3IN88US=> M4q1SXNCVkeHUh?=
BB65-RCC NULDXYM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M323T2lEPTB;Mz65O|U1PyEQvF2= NVX5e5pFW0GQR1XS
EB-3 NYezRoN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTNwOUm2N|Mh|ryP MXjTRW5ITVJ?
SHP-77 NUnEbm5QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\jSllKSzVyPUSuNFA2OjRizszN NWf5T2dxW0GQR1XS
NCI-H2196 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVuxV5hTUUN3ME20MlA2PjJ3IN88US=> NHuwUVZUSU6JRWK=
GI-ME-N MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\VOmZlUUN3ME20MlA3Ozl7IN88US=> MYTTRW5ITVJ?
MN-60 MnvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fwNGlEPTB;ND6xNFg4KM7:TR?= MnnCV2FPT0WU
NCI-H1694 NUD5cZc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTRwMUO0NFUh|ryP M{jscXNCVkeHUh?=
LU-65 NXjMb|UxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3xeIVKSzVyPUSuNVU{OzJizszN NXHUdGZIW0GQR1XS
NCI-H1436 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHOZ2dkUUN3ME20MlE5OzN|IN88US=> MY\TRW5ITVJ?
KINGS-1 M1z4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTRwM{G0N|Ih|ryP NYHrcmd[W0GQR1XS
GT3TKB NHu1fW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHJeGxKSzVyPUSuN|MzPjhizszN MnjpV2FPT0WU
Becker MmXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\UeWlEPTB;ND6zO|MyOiEQvF2= NWfaSmxYW0GQR1XS
HCC1187 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInzOJNKSzVyPUSuPFk3PTdizszN MU\TRW5ITVJ?
D-502MG MoH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3foeWlEPTB;NT6wNFQyPiEQvF2= NVL2NXFuW0GQR1XS
VA-ES-BJ NFvtc4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTVwMUO3O|gh|ryP MnL6V2FPT0WU
NB7 M2D4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTVwMUSxNVIh|ryP MlTyV2FPT0WU
SW962 NWnoZ4VpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTVwM{i4NVQh|ryP NHroc|FUSU6JRWK=
no-11 NGrCVVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3qUnpKSzVyPUWuO|Y{PDNizszN MULTRW5ITVJ?
KNS-81-FD NELyOYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGf0TGhKSzVyPUWuPVA3QTRizszN MkfnV2FPT0WU
COLO-684 M4LBT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1u2dmlEPTB;NT65PVQ6PCEQvF2= M{LwOnNCVkeHUh?=
D-263MG MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zjcWlEPTB;Nj6wPFg6PSEQvF2= MWXTRW5ITVJ?
EW-24 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PFTmlEPTB;Nj6yPFUyKM7:TR?= M2XH[3NCVkeHUh?=
TE-10 NV6yb5NrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHTeFVKSzVyPU[uOFI3OjNizszN MUnTRW5ITVJ?
EKVX MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{WxNGlEPTB;Nj60OlMzOSEQvF2= M{fkWXNCVkeHUh?=
NCI-H1648 Mnm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LZdGlEPTB;Nj62O|U2PyEQvF2= NWr3UmRoW0GQR1XS
LB771-HNC MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{P2bmlEPTB;Nj65NlMxOSEQvF2= MnrxV2FPT0WU
SK-MEL-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LNUmlEPTB;OD6xN|E3PiEQvF2= M{nXWnNCVkeHUh?=
COLO-668 M1ztemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoK0TWM2OD16LkK3O|g3KM7:TR?= NWDtU4g5W0GQR1XS
EW-12 M3Tkbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvKTYFKSzVyPUiuOFA5ODNizszN M{TZXnNCVkeHUh?=
A253 NVWzcVNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkD0TWM2OD16Lki0OlYyKM7:TR?= MlfiV2FPT0WU
NCI-H2126 MkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fueWlEPTB;OD64PVMyQSEQvF2= NYexdJFTW0GQR1XS
Calu-6 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:4OWlEPTB;OD65PVA1OiEQvF2= M1G1fXNCVkeHUh?=
NCI-H23 MnG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTxS|k3UUN3ME25MlE4PzR4IN88US=> NIXo[llUSU6JRWK=
WSU-NHL MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIm5PHBKSzVyPUmuO|c1PzhizszN MVfTRW5ITVJ?
MMAC-SF NXm0W4NDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\kdZhrUUN3ME25Mlk4QTB2IN88US=> NIS1dm5USU6JRWK=
SK-LMS-1 M3HGemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXjdWJKSzVyPUGwMlI5OzRizszN M2XUUHNCVkeHUh?=
GCIY MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlmyTWM2OD1zMD61PVI1KM7:TR?= M3Tme3NCVkeHUh?=
TE-15 NIfj[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDrTWM2OD1zMT62NFA1KM7:TR?= NWT6emFOW0GQR1XS
EoL-1-cell NYPWeJllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nSdWlEPTB;MUGuO|Y5OiEQvF2= NF7rNJlUSU6JRWK=
NCI-H2081 Mnr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2P3RmlEPTB;MUGuO|c5PiEQvF2= MY\TRW5ITVJ?
EW-3 M1zB[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17RdGlEPTB;MUKuNlQ3OyEQvF2= M1f0d3NCVkeHUh?=
CAS-1 Mk[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTF{LkO2N|Eh|ryP MWHTRW5ITVJ?
C2BBe1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfte5RKSzVyPUGyMlYyOzFizszN NIrkTHJUSU6JRWK=
D-247MG M3;3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;lbGhQUUN3ME2xNk44QTV{IN88US=> M1PidXNCVkeHUh?=
NCI-SNU-5 M{\QWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTF{LkiwNVMh|ryP M4POPHNCVkeHUh?=
LS-1034 MlroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mln5TWM2OD1zND6zPVc2KM7:TR?= M{\5c3NCVkeHUh?=
EW-18 MlXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnP4TWM2OD1zND60OFgh|ryP NF7mU5lUSU6JRWK=
Raji M3PVOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\sXGlEPTB;MUSuOVA1QSEQvF2= NWq2VINDW0GQR1XS
D-283MED M1;E[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{m2cGlEPTB;MUSuOlI4OSEQvF2= M3\3dnNCVkeHUh?=
MZ2-MEL Mk\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELvRXpKSzVyPUG0Mlk3QTZizszN M3TidHNCVkeHUh?=
NCI-SNU-16 NHvMTHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTF3LkS2N|Mh|ryP NXi5dYhTW0GQR1XS
P30-OHK M2TObmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXETWM2OD1zNz63PFMyKM7:TR?= MUPTRW5ITVJ?
RXF393 NIHCV2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTF7LkCxPFYh|ryP MV\TRW5ITVJ?
NCI-H1395 M3vjTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTJyLk[3NFMh|ryP MlzCV2FPT0WU
U-698-M MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfL[2xKSzVyPUKwMlcxPzVizszN NVz2VWZiW0GQR1XS
NCI-SNU-1 M{npOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPaTWM2OD1{MD63NlI{KM7:TR?= M3LlfHNCVkeHUh?=
SW684 MlLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnT5TWM2OD1{MT6xO|E3KM7:TR?= NVXXUoliW0GQR1XS
NCI-H716 MnvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTJzLkOxOVQh|ryP Mn3rV2FPT0WU
JVM-2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrNWlFnUUN3ME2yNU41OTN|IN88US=> NIHGRXRUSU6JRWK=
NCI-H1581 NIHwZoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHDUHJKSzVyPUKyMlQyPDhizszN MkXQV2FPT0WU
CA46 M4DDcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\T[mlEPTB;M{GuOlk{PiEQvF2= NEDURmtUSU6JRWK=
SNB75 MoT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFiyeWlKSzVyPUOzMlY2ODNizszN MkL6V2FPT0WU
KNS-42 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M324R2lEPTB;M{WuPVYzPCEQvF2= NGrRXIpUSU6JRWK=
TUR MmrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfJTWM2OD1|Nj6wOVIyKM7:TR?= NF7JPYpUSU6JRWK=
REH MnLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3ToemlEPTB;M{euPFIyOSEQvF2= NXjTfFUzW0GQR1XS
EW-22 M1O1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLIUYF6UUN3ME20Nk4zQDh3IN88US=> MYrTRW5ITVJ?
NCI-H446 MmjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljnTWM2OD12Mj63PFU{KM7:TR?= Ml7aV2FPT0WU
ES3 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXqwUVYzUUN3ME20N{4yOzN7IN88US=> M13Pd3NCVkeHUh?=
EW-11 NFzTUIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDxdW9rUUN3ME20OE45OjF6IN88US=> M{XZWXNCVkeHUh?=
RH-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPsTWM2OD12Nz61PFEzKM7:TR?= MYDTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
AcH3 / AcH4 / HDAC1 / HDAC2 / HDAC3; 

PubMed: 24203492     


HCT-15 or fresh primary NK cells were treated with entinostat for 24 h, and AcH3, AcH4, and HDAC1, 2, and 3 were detected by Western blotting. 

Cleaved PARP; 

PubMed: 19148581     


Induction of PARP cleavage in Daoy cells upon exposure to MS-275 was demonstrated by Western blot analyses using antibodies that recognize the cleaved 89 kDa PARP protein. Pan-Actin (45 kDa) was used as a loading control.

Caspase 8 ; 

PubMed: 19148581     


Cleavage of pro-Caspase-8 was demonstrated by Western blotting with extracts prepared from Daoy cells treated with 2.5 µM MS-275 for various time periods. Antibodies specific to human Caspase-8 or the loading control, pan-Actin were used to probe protein expression.

DR4 / DR5; 

PubMed: 19148581     


Western blotting to detect DR4 and DR5 expression upon treatment of Daoy cells with 2.5 µM MS-275 for 4, 8 and 24 h.

TopoIIα / TopoIIβ; 

PubMed: 21254166     


Upper panel, concentration-dependent effects of AR42, MS-275 and vorinostat on the expression of topoIIα versus topoIIβ after 48 h. Lower panel, time-dependent effect of 0.5 μM AR42 and 5 μM MS-275 on topoIIα versus topoIIβ expression in PLC-5 cells.

24203492 19148581 21254166
Immunofluorescence
phalloidin / snail; 

PubMed: 29855565     


(C) Effect of MS-275 treatment on Snail expression and localization. MCs (mesothelial cells) were treated with MS-275 (250 nM), or DMSO for 48 hr and then stimulated with TGFβ1 (2 ng/ml) for 24 h before processing for immunofluorescence with a monoclonal antibody against Snail. Cell nuclei are shown in blue (Hoechst 33342). Confocal images are shown from one representative experiment of three performed.

DR4 / DR5; 

PubMed: 19148581     


Flow Cytometry to measure cell surface expression of FAS, DR4 and DR5 using PE-labeled antibodies. Cells stained with isotype matched anti-human IgG antibodies served as controls.

H3K4Me3 / H3K9Me3; 

PubMed: 22468166     


Immunocytochemical analysis of the effects of AR42, SAHA, and MS-275 at the indicated concentrations on H3K4Me3 (upper panels) and H3K9Me3 (lower panels) after 24 h of treatment in LNCaP cells.

29855565 19148581 22468166
Growth inhibition assay
Cell proliferation; 

PubMed: 24203492     


(A) HCT-15 cells were cultured in indicated concentrations of entinostat for up to 72 h, and proliferation determined by MTT assay as indicated. (B) HCT-15, CCH-OS-D, COL and HOS cells were cultured in indicated concentrations of entinostat for 72 h, and viable cell number was determined using the Vi-cell assay and proliferation index calculated. (C) Freshly-isolated human NK cells were cultured in indicated concentrations of entinostat for up to 72 h, and viability was assessed by flow cytometry for 7-AAD uptake. *, P < 0.05, **; P ≤ 0.01; ***, P ≤ 0.001

Cell viability; 

PubMed: 28969017     


PANC-1, MIA PaCa-2, BxPC3, CFPAC-1, SUIT2 and SUIT2 Clone 1 cells were plated at a density of 3-5×103 per well in 96-well microtiter plates, allowed to adhere overnight and incubated for 72 hours in the presence of variable concentrations of entinostat (0-100μM). Cell viability was determined by XTT assays. The data presented are the mean values from triplicate wells from two independent experiments ±SE.

24203492 28969017
ELISA
GCP-2 / MCP-2 / MIF ; 

PubMed: 24241152     


MS-275 and SAHA suppressed the secretion of GCP-2, MCP-2 and MIF in E11 cells. (A) GCP suppression. (B) MCP-2 suppression. (C) MIF suppression. E11 cells were incubated with HDAC inhibitors at various concentrations for 1 h before they were stimulated by LPS. 24 h later, the secretion of GCP-2, MCP-2 and MIF were quantified by ELISA (n = 8). Bars show the mean and SD in (A–C).

24241152
In vivo MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

Protocol

Kinase Assay:

[6]

- Collapse

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research:

[2]

- Collapse
  • Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • Concentrations: ~ 10 μM
  • Incubation Time: 3 days
  • Method:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • Dosages: 12.3, 24.5 and 49 mg/kg
  • Administration: Administered orally once daily 5 days per week for 4 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 376.41
Formula

C21H20N4O3

CAS No. 209783-80-2
Storage powder
in solvent
Synonyms SNDX-275
Smiles C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03829930 Recruiting Drug: Entinostat|Drug: Enzalutamide Prostate Adenocarcinoma George Washington University May 1 2019 Phase 1
NCT03765229 Recruiting Drug: Entinostat|Drug: Pembrolizumab Melanoma UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals Inc. March 22 2019 Phase 2
NCT03473639 Recruiting Drug: Entinostat|Drug: Capecitabine Metastatic Breast Cancer|Breast Cancer University of Virginia|Syndax Pharmaceuticals January 29 2019 Phase 1
NCT03361800 Active not recruiting Drug: Entinostat Breast Cancer|Invasive Breast Cancer|ER-Negative PR-Negative HER2-Negative Breast Cancer UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals|National Cancer Institute (NCI) November 28 2018 Early Phase 1
NCT03192111 Completed Drug: Entinostat Renal Impairment|Healthy Volunteer Syndax Pharmaceuticals July 27 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • Answer:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Entinostat (MS-275) | Entinostat (MS-275) supplier | purchase Entinostat (MS-275) | Entinostat (MS-275) cost | Entinostat (MS-275) manufacturer | order Entinostat (MS-275) | Entinostat (MS-275) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID